Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» non-small cell lung cancer
non-small cell lung cancer
J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval
Endpoints
Thu, 01/28/21 - 11:16 pm
JNJ
amivantamab
non-small cell lung cancer
Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag
Endpoints
Thu, 01/28/21 - 10:41 am
Takeda
lung cancer
mobocertinib
non-small cell lung cancer
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq
Pharmaceutical Business Review
Wed, 01/6/21 - 10:37 am
Roche
FDA
tiragolumab
Tecentriq
non-small cell lung cancer
breakthrough therapies
Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication
Endpoints
Mon, 12/21/20 - 10:59 am
AstraZeneca
Tagrisso
non-small cell lung cancer
JNJ
amivantamab
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Thu, 12/3/20 - 10:55 am
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Tue, 11/10/20 - 10:45 am
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Tue, 11/3/20 - 10:24 am
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Thu, 10/29/20 - 12:17 pm
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Triple meeting – the point of turning to TPX-0022
EP Vantage
Tue, 10/27/20 - 10:32 am
Turning Point Therapeutics
repotrectinib
TPX-0022
non-small cell lung cancer
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Mon, 10/19/20 - 10:47 am
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
BioSpace
Wed, 10/7/20 - 11:41 pm
Bristol-Myers Squibb
clinical trials
non-small cell lung cancer
Opdivo
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Fierce Biotech
Tue, 10/6/20 - 10:26 am
Amgen
clinical trials
non-small cell lung cancer
KRAS
sotorasib
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
Tue, 09/22/20 - 11:10 am
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Mon, 09/21/20 - 10:57 am
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Mon, 09/21/20 - 10:33 am
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
Sat, 09/19/20 - 09:05 pm
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Sun, 09/6/20 - 07:22 pm
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Endpoints
Wed, 08/19/20 - 12:18 pm
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
clinical trials
Pfizer
Roche
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Stat
Wed, 08/12/20 - 11:51 pm
lung cancer
non-small cell lung cancer
targeted therapeutics
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Sun, 08/9/20 - 11:14 pm
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »